第2代组胺H1拮抗剂氯雷他定治疗持续性变应性鼻炎的心血管安全性观察

Observation on cardiovascular safety of loratadine in treatment of persistent allergic rhinitis

目的:客观评价第2代组胺H1拮抗剂氯雷他定治疗变应性鼻炎的心血管安全性。方法:50例持续性变应性鼻炎患者,其中19例(38.0%)有心血管疾病史和(或)心电图异常,但均无QT间期延长。给予氯雷他定片10 mg口服,每日1次,疗程30 d。所有患者治疗前、后均行心电图监测,分析心电图资料,评价氯雷他定对心血管的影响。结果:用药后患者窦性心律均未发生改变。治疗后与治疗前相比,心率、P波时限、PR间期和QRS时限的变化均差异无统计学意义(均P>0.05),无显著QT间期或QTc间期延长(P>0.05)。结论:长期使用临床推荐剂量氯雷他定治疗持续性变应性鼻炎未发现心血管不良反应。

Objective.. To evaluate cardiovascular safety of loratadine, a second generation Hi-antagonist, in treatment of patients with allergic rhinitis. Method：A total of 50 patients with persistent allergic rhinitis were enrolled, of which 19 cases （38.0%） had a history of cardiovascular diseases and/or presented abnormal electrocardiogram （ECG） findings without prolonged QT-interval. For all patents, 10 mg loratadine tablet was oral administrated once-daily for 30 days. ECG examinations were carried out both before and after treatment. Cardiovascular effects of loratadine were determined by the comparison of two ECGs. Result： All patients had no alterations in sinus rhythm after administration of loratadine for 30 days . There were no significant differences of heart rates, P durations, PR or QRS intervals between the baseline and end-point ECGs（ P〉0.05）, as well as no significant prolongation of the QT or QTc corrected for heart rate using Bazett＇ formula（ P〉0.05）. Conclusion.. Cardiovascular safety of loratadine, a second generation HI-antagonist, is confirmed in long term treatment of persistent allergic rhinitis at a recommended dose.